Related Experiment Video

Updated: Jul 13, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Targeted treatment of prostate cancer

Xinning Wang1, Lihong Yin, Pravin Rao

  • 1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Journal of Cellular Biochemistry
|August 10, 2007
PubMed

Insights

Prostate cancer treatment is evolving beyond androgen deprivation therapy. Research now explores new targets like prostate specific membrane antigen (PSMA) for innovative therapies.

Area of Science:

  • Oncology
  • Urology
  • Molecular Biology

Background:

  • Prostate cancer treatment historically relies on androgen deprivation therapy, pioneered by Charles Huggins.
  • The androgen receptor (AR) has been a central research focus for prostate cancer therapies.
  • Emerging research suggests novel therapeutic targets beyond the AR.

Purpose of the Study:

  • To provide an overview of evolving prostate cancer treatment strategies.
  • To highlight emerging therapeutic targets and approaches.
  • To emphasize strategies utilizing prostate specific membrane antigen (PSMA).

Main Methods:

  • Literature review of historical and recent prostate cancer research.
  • Analysis of preliminary trial data for novel therapeutic agents.
  • Focus on PSMA-targeted therapies.

Main Results:

  • Androgen deprivation therapy remains a cornerstone, but resistance develops.
  • New targets and therapeutic modalities are under investigation.
  • PSMA is emerging as a promising target for novel prostate cancer treatments.

Conclusions:

  • Prostate cancer treatment is expanding beyond AR-targeted therapies.
  • PSMA-targeted strategies represent a significant advancement.
  • Further research into novel targets like PSMA is warranted for improved patient outcomes.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...